Ribonucleotide reductase inhibitors and methods of use

A technology for deprotecting agents and compounds, which is applied in the field of ribonucleotide reductase inhibitors and applications, and can solve problems such as the lack of progress in the research and development of RR inhibitors.

Active Publication Date: 2014-11-05
CITY OF HOPE
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, little progress has been made in the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ribonucleotide reductase inhibitors and methods of use
  • Ribonucleotide reductase inhibitors and methods of use
  • Ribonucleotide reductase inhibitors and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0206] Example 1: Identification of RRM2 as a target for anticancer therapy:

[0207] The RRM2-luciferase fusion construct ("pR2Luc") was administered to explants by high pressure tail vein injection (HPTV) alone or in combination with RRM2 siRNA ("siR2B+5") [plasmid 0.25 mg / kg, siRNA 1.25 mg / kg]. Female BALB / c mice harboring human HepG2 hepatoma cells were injected. In vivo bioluminescent imaging reveals robust downregulation of ( figure 1 ). Mice receiving RRM2 in combination with RRM2 siRNA exhibited a significant reduction in tumor growth compared to mice receiving RRM2 alone or RRM2 in combination with a control siRNA ("si control"). These results suggest that RRM2 plays a critical role in cancer growth and validate it as a therapeutic target.

[0208] RRM2 mRNA expression levels were measured by RT-PCR in 35 human fresh-frozen breast cancer biopsy samples and corresponding normal tissue samples. Determination of optimal PCR primer and probe concentrations for RRM2 an...

Embodiment 2

[0210] Example 2: Identification of novel RR inhibitors:

[0211] A virtual screening process was performed on a diverse compound library from NCI's Developmental Therapeutics Program (DTP) to identify potential RR inhibitors. The DTP library contains 2,000 different compounds. A novel ligand-binding pocket (PDB2UW2) on human RRM2 identified from X-ray crystal structure was selected to identify a site close to the RRM1 / RRM2 interface but away from the dityrosyl-diiron center to avoid side effects of iron chelation Potential inhibitor compounds. This ligand-binding pocket consists of 32 amino acid residues that are conserved among the human and mouse RRM2 protein families, and lies next to the RRM1 / RRM2 interface. The structure of the ligand binding pocket is shown in Figure 4 middle. The pocket consists of helices α7, α8 and α10 at the C-terminal domain. The narrow inner end of the V-shaped pocket is lined with hydrophobic residues near the rear of the center of the dity...

Embodiment 3

[0215] Example 3: Characterization of novel NCI-3 analogs:

[0216]NCI-3 and the NCI-3 analogs synthesized in Example 2 were tested for their ability to inhibit RR activity using the in vitro holoenzyme assay described above. COH4 exhibited a significant RR inhibitory effect. COH20 was even more potent, inhibiting the recombinant RRM1 / RRM2 complex by 90.2% in vitro ( Image 6 ). The IC50 results for various compounds are shown in Table 1.

[0217] Table 1:

[0218] compound

IC50±S.D.(μM)

HU

148.0±7.34

3-AP

1.2±0.13

NCI-3

19.1±0.43

COH4

15.3±1.8

COH20

9.3±2.3

[0219] In stark contrast to 3-AP, the inhibitory effect of COH20 on RR was barely affected by iron addition (Table 2).

[0220] Table 2:

[0221]

[0222] Site-directed mutagenesis, Biacore analysis, and NMR saturation shift difference (STD) analysis were performed to verify the binding pocket and ligand / protein interaction between COH20 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.

Description

[0001] related application [0002] This application claims the benefit of US Application No. 13 / 364,263, filed February 1, 2012, the disclosure of which is hereby incorporated by reference in its entirety for all purposes. [0003] government interest [0004] This invention was made with government support under Grant No. CA127541 awarded by the National Institutes of Health. The government has certain rights in this invention. Background technique [0005] Ribonucleotide diphosphate reductase (RR) is a highly regulated enzyme in the deoxyribonucleotide synthesis pathway ubiquitously present in humans, bacteria, yeast and other organisms (Jordan 1998). RR is responsible for the reconversion of ribonucleotide diphosphates to 2'-deoxyribonucleotide diphosphates, a process that is essential for DNA synthesis and repair (Thelander 1986; Jordan 1998; Liu 2006). RR is directly involved in tumor growth, metastasis and drug resistance (Yen 1994; Zhou 1995; Nocentini 1996; Fan 199...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D277/46A61K31/426A61P35/00
CPCC07D277/46C07D277/40A61P35/00C07D417/12C07C45/68
Inventor D·霍内C·林肯
Owner CITY OF HOPE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap